Hot Features
プレミアム
Enanta Pharmaceuticals Inc (ENTA)
NASDAQ
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
| 日付 | 保有者名 | 取引株数 | 金額レンジ ($) | 取引種別 | 価格レンジ ($) | 届出終了時の株数 | % 変化 |
|---|---|---|---|---|---|---|---|
| 2026-02-12 | Mr. Matthew P. KowalskyChief Legal Officer & Corporate Secretary | -1.90k | 27.10k | Sale to Issuer | 14.25 | 3.59k | -34.63% |
| 2026-02-12 | Mr. Brendan LuuChief Business Officer | -3.26k | 46.41k | Sale to Issuer | 14.25 | 37.01k | -8.09% |
| 2026-02-12 | Ms. Tara Lynn KiefferChief Product Strategy Officer | -3.26k | 46.41k | Sale to Issuer | 14.25 | 29.30k | -10.00% |
| 2026-02-12 | Dr. Scott T. RottinghausChief Medical Officer | -3.41k | 48.64k | Sale to Issuer | 14.25 | 18.50k | -15.57% |
| 2026-02-12 | Dr. Yat Sun OrChief Scientific Officer | -3.41k | 48.64k | Sale to Issuer | 14.25 | 369.60k | -0.91% |
| 2026-02-12 | Dr. Jay R. LulyPresident, CEO & Director | -6.16k | 87.71k | Sale to Issuer | 14.25 | 856.12k | -0.71% |
| 2025-12-05 | Ms. Kathleen S. CappsExecutive Director of Accounting, Controller & Interim Principal Accounting Officer | -323.00 | 4.60k | 売り | 14.23 | 1.43k | -18.44% |
| 2025-12-05 | Mr. Harry R. TroutVP of Finance & Interim Principal Financial Officer | -542.00 | 7.71k | 売り | 14.23 | 3.15k | -14.68% |
| 2025-12-05 | Dr. Scott T. RottinghausChief Medical Officer | -798.00 | 11.36k | 売り | 14.23 | 15.04k | -5.04% |
| 2025-12-05 | Mr. Brendan LuuChief Business Officer | -1.39k | 19.84k | 売り | 14.23 | 33.70k | -3.97% |
| 2025-12-05 | Ms. Tara Lynn KiefferChief Product Strategy Officer | -2.11k | 29.97k | 売り | 14.23 | 26.00k | -7.49% |
| 2025-12-05 | Dr. Yat Sun OrChief Scientific Officer | -2.39k | 34.01k | 売り | 14.23 | 366.14k | -0.65% |
| 2025-12-05 | Dr. Jay R. LulyPresident, CEO & Director | -4.74k | 67.49k | 売り | 14.23 | 826.53k | -0.57% |
| 2025-12-02 | Ms. Kathleen S. CappsExecutive Director of Accounting, Controller & Interim Principal Accounting Officer | -207.00 | 2.89k | 売り | 13.96 | 690.00 | -23.08% |
| 2025-12-01 | Ms. Kathleen S. CappsExecutive Director of Accounting, Controller & Interim Principal Accounting Officer | -85.00 | 1.20k | Sale to Issuer | 14.12 | 690.00 | -10.97% |
| 2025-12-02 | Mr. Harry R. TroutVP of Finance & Interim Principal Financial Officer | -380.00 | 5.30k | 売り | 13.96 | 1.91k | -16.61% |
| 2025-12-01 | Mr. Harry R. TroutVP of Finance & Interim Principal Financial Officer | -105.00 | 1.48k | Sale to Issuer | 14.12 | 1.91k | -5.22% |
| 2025-12-01 | Mr. Brendan LuuChief Business Officer | -498.00 | 7.03k | Sale to Issuer | 14.12 | 30.47k | -1.61% |
| 2025-12-01 | Ms. Tara Lynn KiefferChief Product Strategy Officer | -753.00 | 10.63k | Sale to Issuer | 14.12 | 23.48k | -3.11% |
| 2025-12-01 | Dr. Yat Sun OrChief Scientific Officer | -753.00 | 10.63k | Sale to Issuer | 14.12 | 363.28k | -0.21% |
| 2025-12-01 | Dr. Jay R. LulyPresident, CEO & Director | -1.89k | 26.62k | Sale to Issuer | 14.12 | 831.27k | -0.23% |
| 2025-08-08 | Dr. Scott T. RottinghausChief Medical Officer | -2.22k | 15.50k | Sale to Issuer | 6.99 | 14.09k | -13.60% |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
メールアドレスで登録
すでにアカウントをお持ちですか？ サインイン
アカウントをお持ちでないですか？ 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。
